{"schema_version":"secwatch.filing_event.v1","accession":"0001625297-25-000059","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.511465+00:00","generated_at":"2026-05-17T09:57:28.976506+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Indivior announces restructuring charges of $39-$50 million as part of Indivior Action Agenda","bullets":["Headcount reductions expected to incur pre-tax severance charges of approximately $16 to $19 million in Q3 2025.","Real estate consolidation and exit costs estimated at $15 to $22 million pre-tax, including leasehold improvements and asset write-downs.","Consulting, legal, and tax planning expenses of about $8 to $9 million pre-tax, recognized in Q3 2025.","Company is exploring strategic alternatives for OPVEE and its non-U.S. business, which could result in further one-time costs.","Restructuring charges will be excluded from non-GAAP financial measures, consistent with reporting practices."],"urls":{"canonical":"https://secwatch.observer/filing/0001625297-25-000059","json":"https://secwatch.observer/filing/0001625297-25-000059.json","markdown":"https://secwatch.observer/filing/0001625297-25-000059.md","text":"https://secwatch.observer/filing/0001625297-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000059/0001625297-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000059/indv-20250826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T09:57:28.976506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8b8c39260cde0a290636460263dec367a14b57c","claim":"Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $39 to $50 million of restructuring charges pre-tax, of which $27-$35 million will be cash affecting enterprise-wide (pre-tax employee severance and related employee exit charges of approximately $16 to $19 million).","evidence_excerpt":"which will be recognized in the third quarter of 2025. As a result of this initial initiative related to Phase 1, the Company expects to recognize a total of approximately $39 to $50 million of restructuring charges pre-tax, of which $27-$35 million will be cash, and which are expected to be recognized in the third and fourth quarters of 2025. These","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000059/0001625297-25-000059-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $39 to $50 million of restructuring charges pre-tax, of which $27-$35 million will be cash"},{"label":"Affected area","value":"enterprise-wide"},{"label":"Headcount","value":"pre-tax employee severance and related employee exit charges of approximately $16 to $19 million"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}